We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

SCT Completes the 90 Day Endpoint Period for the Last Patient Enrolled in the Modified REGENESIS Phase IIb Stroke Trial

News   Apr 27, 2010

 
SCT Completes the 90 Day Endpoint Period for the Last Patient Enrolled in the Modified REGENESIS Phase IIb Stroke Trial
 
 
 

RELATED ARTICLES

New 3D-printed Device Could Help Treat Spinal Cord Injuries

News

Researchers hope their neuronal stem cell scaffold could be surgically implanted to help spinal cord injury patients.

READ MORE

Bird Study Shows Optimal Sperm Length Varies Between Individuals

News

Sperm success is not always dictated by sperm length, bird study shows.

READ MORE

Zika Vaccine Clinical Trial Begins

News

Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE